These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 30596429)

  • 1. Integrated Metabolomics and Lipidomics Analyses Reveal Metabolic Reprogramming in Human Glioma with IDH1 Mutation.
    Zhou L; Wang Z; Hu C; Zhang C; Kovatcheva-Datchary P; Yu D; Liu S; Ren F; Wang X; Li Y; Hou X; Piao H; Lu X; Zhang Y; Xu G
    J Proteome Res; 2019 Mar; 18(3):960-969. PubMed ID: 30596429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma.
    Khurshed M; Molenaar RJ; Lenting K; Leenders WP; van Noorden CJF
    Oncotarget; 2017 Jul; 8(30):49165-49177. PubMed ID: 28467784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.
    Chaumeil MM; Radoul M; Najac C; Eriksson P; Viswanath P; Blough MD; Chesnelong C; Luchman HA; Cairncross JG; Ronen SM
    Neuroimage Clin; 2016; 12():180-9. PubMed ID: 27437179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
    Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
    Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Metabolomic Analysis of IDH1
    Miyata S; Tominaga K; Sakashita E; Urabe M; Onuki Y; Gomi A; Yamaguchi T; Mieno M; Mizukami H; Kume A; Ozawa K; Watanabe E; Kawai K; Endo H
    Sci Rep; 2019 Jul; 9(1):9787. PubMed ID: 31278288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic changes related to the IDH1 mutation in gliomas preserve TCA-cycle activity: An investigation at the protein level.
    Dekker LJM; Wu S; Jurriëns C; Mustafa DAN; Grevers F; Burgers PC; Sillevis Smitt PAE; Kros JM; Luider TM
    FASEB J; 2020 Mar; 34(3):3646-3657. PubMed ID: 31960518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase.
    Izquierdo-Garcia JL; Cai LM; Chaumeil MM; Eriksson P; Robinson AE; Pieper RO; Phillips JJ; Ronen SM
    PLoS One; 2014; 9(9):e108289. PubMed ID: 25243911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolomics of Glioma.
    Feng S; Liu Y
    Adv Exp Med Biol; 2021; 1280():261-276. PubMed ID: 33791988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters.
    Viswanath P; Najac C; Izquierdo-Garcia JL; Pankov A; Hong C; Eriksson P; Costello JF; Pieper RO; Ronen SM
    Oncotarget; 2016 Jun; 7(23):34942-55. PubMed ID: 27144334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma.
    Yang R; Zhao Y; Gu Y; Yang Y; Gao X; Yuan Y; Xiao L; Zhang J; Sun C; Yang H; Qin J; Li J; Zhang F; Zhang L; Ye J
    Oncogene; 2020 Oct; 39(40):6340-6353. PubMed ID: 32855525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI.
    Yao J; Chakhoyan A; Nathanson DA; Yong WH; Salamon N; Raymond C; Mareninov S; Lai A; Nghiemphu PL; Prins RM; Pope WB; Everson RG; Liau LM; Cloughesy TF; Ellingson BM
    Neuro Oncol; 2019 Sep; 21(9):1184-1196. PubMed ID: 31066901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis.
    Perrech M; Dreher L; Röhn G; Stavrinou P; Krischek B; Toliat M; Goldbrunner R; Timmer M
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819828396. PubMed ID: 30943868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZEB1 expression is increased in IDH1-mutant lower-grade gliomas.
    Nesvick CL; Zhang C; Edwards NA; Montgomery BK; Lee M; Yang C; Wang H; Zhu D; Heiss JD; Merrill MJ; Ray-Chaudhury A; Zhuang Z
    J Neurooncol; 2016 Oct; 130(1):111-122. PubMed ID: 27568035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma.
    Dao Trong P; Rösch S; Mairbäurl H; Pusch S; Unterberg A; Herold-Mende C; Warta R
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma.
    Chaumeil MM; Larson PE; Woods SM; Cai L; Eriksson P; Robinson AE; Lupo JM; Vigneron DB; Nelson SJ; Pieper RO; Phillips JJ; Ronen SM
    Cancer Res; 2014 Aug; 74(16):4247-57. PubMed ID: 24876103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
    Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
    J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence.
    Turcan S; Makarov V; Taranda J; Wang Y; Fabius AWM; Wu W; Zheng Y; El-Amine N; Haddock S; Nanjangud G; LeKaye HC; Brennan C; Cross J; Huse JT; Kelleher NL; Osten P; Thompson CB; Chan TA
    Nat Genet; 2018 Jan; 50(1):62-72. PubMed ID: 29180699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas.
    Ren F; Zhao Q; Huang L; Zheng Y; Li L; He Q; Zhang C; Li F; Maimela NR; Sun Z; Jia Q; Ping Y; Zhang Z; Chen X; Yue Y; Liu S; Cao L; Zhang Y
    Immunol Cell Biol; 2019 May; 97(5):457-469. PubMed ID: 30575118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
    Miller JJ; Shih HA; Andronesi OC; Cahill DP
    Cancer; 2017 Dec; 123(23):4535-4546. PubMed ID: 28980701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.